Electra Therapeutics (ETRA) Director Nancy Stagliano Converts Preferred to 255,635 Shares

What Happened

• Nancy Stagliano, a director of Electra Therapeutics (ETRA), reported the automatic conversion of 255,635 shares of Series A Convertible Preferred Stock into 255,635 shares of common stock on September 21, 2026.
• The filing shows an acquisition of 255,635 common shares and a simultaneous disposition of 255,635 derivative securities (the preferred). No price or cash value is reported (N/A) because the conversion occurred automatically upon the company’s IPO without additional consideration.
• This is a conversion event (neither a market buy nor a sale) and is generally a neutral corporate action rather than a trading signal.

Key Details

• Transaction date and filing date: 2026-09-21 (reported on the same day).
• Transaction type: Conversion of derivative security (Code C) — acquired 255,635 common shares; disposed 255,635 derivative (preferred) shares.
• Price/Value: N/A — conversion occurred without payment.
• Shares owned after transaction: The Form 4 reports the 255,635 common shares resulting from conversion.
• Footnote: F1 — Each Series A preferred automatically converted 1-for-1 into common stock upon the IPO; the preferred had no expiration date.
• Timeliness: Filed on the transaction date (no late filing indicated).

Context

• This was not an open-market buy or sale; it reflects the corporate conversion of preferred stock into common following the IPO. Such conversions increase the insider’s common shares outstanding but do not directly indicate a change in sentiment or insider trading intent.
• For investors, conversions can modestly increase the free float of common shares; they are administrative/corporate events rather than trading activity.